Brean Murray Carret & Co. Starts Gilead Sciences (GILD) at Buy; Broad Offerings in HIV Set to Drive Upside

Brean Murray Carret & Co. initiates coverage on Gilead Sciences (NASDAQ: GILD) with a Buy. PT $52.00.

Brean analyst says, "We believe GILD shares are set to outperform over the next 12 months, given a potential U.S. approval of a novel, fixed-dose combination therapy over the next few weeks, the anticipated move forward with collaboration around a novel PI-based FDC with Tibotec, and expected positive data from GILD's most-watched, development-stage asset, the Quad."

For more ratings news on Gilead Sciences click here and for the rating history of Gilead Sciences click here.

Shares of Gilead Sciences closed at $36.82 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Axis Capital Limited Assumes Jubilant Foodworks Ltd (JUBI:IN) at Reduce (3)
• Lake Street Starts RF Industries Ltd. (RFIL) at Buy